A broad goal of my laboratory is to integrate the pathophysiology of a disease state with the known pharmacology of drugs to the development optimal delivery systems for existing and novel therapies for cancer, and translate those findings from discovery and preclinical development to clinical use. Specifically, my research interests are in optimizing drug dosing schedules and developing nanomedicines and exploiting such drug carriers for the detection and treatment of primary cancers and metastatic disease. We have a specific interest in the development and combination of vascular targeting and conventional oncolytic agents to induce immediate tumor regression and/or facilitate long-ter...